F. Rivera

发表

Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.

Paolo Vineis, Simonetta Guarrera, Giuseppe Matullo, 2014, Human molecular genetics.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

C. Bokemeyer, M. Benasso, A. Schueler, 2008, The New England journal of medicine.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2013, The New England journal of medicine.

Genome-wide association study yields variants at 20 p 12 . 2 that associate with urinary bladder cancer

Katja, Gerald, Anne, 2014 .

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

J. Maurel, F. Rivera, C. Grávalos, 2013, Clinical and Translational Oncology.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fl uorouracil or FOLFIRI in relation to microsatellite status : results of the PETACC-3 trial †

C. Bokemeyer, J. Tabernero, B. Melichar, 2014 .

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

V. Georgoulias, E. Van Cutsem, J. Canon, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients

F. J. Ramos, A. Carrato, J. Tabernero, 2017, Targeted Oncology.

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

A. Carrato, J. Aparicio, B. Massuti, 2013, Clinical and Translational Oncology.

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).

A. Carrato, M. Hidalgo, M. Varella‐Garcia, 2011, Critical reviews in oncology/hematology.

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

F. J. Ramos, J. Baselga, J. Tabernero, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Dendritic cell therapy in melanoma.

F. Rivera, J. Gómez-Román, R. Calderón-Gonzalez, 2017, Annals of translational medicine.

Gold glyconanoparticles coupled to listeriolysin O 91-99 peptide serve as adjuvant therapy against melanoma.

F. Rivera, I. García, S. Penadés, 2017, Nanoscale.

Erratum to: SEOM guidelines for the treatment of gastric cancer 2015

A. Carrato, C. García-Girón, F. Rivera, 2016, Clinical and Translational Oncology.

Seom guidelines for the treatment of gastric cancer 2015

A. Carrato, C. García-Girón, F. Rivera, 2015, Clinical and Translational Oncology.

Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer

Y. Blanco, F. Rivera, Noelia Vega, 2007, Acta oncologica.

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.

V. Heinemann, J. Douillard, F. Rivera, 2016, European journal of cancer.

Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

C. Tournigand, T. Hickish, C. Boni, 2010 .

Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966

L. Saltz, S. Clarke, D. Cunningham, 2008 .

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

A. Carrato, J. Tabernero, A. Abad, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.

M. Hidalgo, B. Massuti, M. Valladares-Ayerbes, 2012, The oncologist.

Current situation of zalutumumab

Y. Blanco, F. Rivera, Noelia Vega, 2009, Expert opinion on biological therapy.

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

F. Rivera, M. López-Brea, R. Márquez, 2008, Acta oncologica.

Cetuximab, its clinical use and future perspectives.

F. Rivera, M. López-Brea, M. E. Vega-Villegas, 2008, Anti-cancer drugs.

Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.

A. Carrato, J. Aparicio, F. Rivera, 2001, Clinical colorectal cancer.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

W. Scheithauer, L. Saltz, S. Clarke, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC

C. Köhne, G. Prager, H. Wasan, 2021, Current oncology.

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma

M. Peeters, A. Zaniboni, M. Valladares-Ayerbes, 2018, ESMO Open.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

J. Hecht, G. Fasola, J. Canon, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

B. Massuti, F. Rivera, C. Grávalos, 2015, European journal of cancer.

Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status

C. Köhne, M. Peeters, F. Rivera, 2017, Clinical colorectal cancer.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

T. Hickish, C. Boni, J. Tabernero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

W. Scheithauer, L. Saltz, S. Clarke, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

J. Douillard, F. Rivera, J. Bachet, 2019, International journal of cancer.

Patients and Methods: the European Organisation for Research and Treatment of Cancer Qol Questionnaire

C. Bokemeyer, M. Benasso, R. Hitt, 2022 .

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial

F. Rivera, Noelia Vega, M. E. Vega-Villegas, 2009, Expert review of anticancer therapy.

Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study

A. Carrato, J. Tabernero, A. Abad, 2005 .

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

C. Montagut, F. Rivera, M. Salgado, 2018, The oncologist.

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

J. Hecht, G. Fasola, J. Canon, 2017, International Journal of Colorectal Disease.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials

J. Canon, M. Peeters, G. Pentheroudakis, 2018, British Journal of Cancer.

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

J. Tabernero, J. Canon, G. Bodoky, 2016, ESMO Open.

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

E. Polo, M. Guillot, M. Valladares-Ayerbes, 2021, ESMO open.

Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

F. López-Ríos, F. Rojo, J. Palacios, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

M. Alsina, F. Rivera, P. Jiménez-Fonseca, 2020, Clinical and Translational Oncology.

SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma

F. Rivera, R. García-Carbonero, C. Grávalos, 2012, Clinical and Translational Oncology.

Recommendations on current approach to gastric cancer

A. Carrato, F. Rivera, C. Pericay, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

C. Bokemeyer, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

B. Massuti, D. Castellano, F. Rivera, 2013, BMC Cancer.

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild‑type (WT) KRAS metastatic colorectal cancer (mCRC).

G. Fasola, J. Canon, F. Rivera, 2013 .

Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).

G. Fasola, J. Canon, F. Rivera, 2013 .

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato, R. Salazar, C. García-Girón, 2021, Drugs & Aging.

5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer

I. Chirivella, A. Figer, F. Rivera, 2004 .

Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial

D. Cunningham, M. Michael, S. Berry, 2007 .

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

P. Gibbs, L. Diaz, E. Van Cutsem, 2020, The New England journal of medicine.

Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

A. Carrato, A. Abad, C. Montagut, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

CMV front-line chemotherapy in transitional bladder carcinoma.

F. Rivera, H. Cortés-Funes, J. Passás, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Diabetes Mellitus Following Cisplatin Treatment

F. Rivera, M. López-Brea, D. Nan, 2003, Acta oncologica.

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

E. Van Cutsem, J. Tabernero, M. Makrutzki, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

J. Albanell, J. García-Foncillas, F. Rivera, 2021, European journal of hospital pharmacy : science and practice.

GNP-GAPDH1-22 nanovaccines prevent neonatal listeriosis by blocking microglial apoptosis and bacterial dissemination.

M. Fresno, F. Rivera, I. García, 2017, Oncotarget.

Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma

F. Rivera, I. García, J. Gómez-Román, 2018, Oncoimmunology.

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.

F. López-Ríos, L. Paz-Ares, M. Alsina, 2018, The oncologist.

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

P. Gibbs, L. Diaz, C. Punt, 2022, The Lancet. Oncology.

First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

L. Mazzolai, P. Prandoni, E. Grandone, 2020 .

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

S. Störkel, M. Benasso, C. Stroh, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

A. Carrato, R. Salazar, A. Abad, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.

J. Hecht, G. Fasola, J. Canon, 2015 .

Chemotherapy of advanced gastric cancer.

F. Rivera, M. López-Brea, M. E. Vega-Villegas, 2007, Cancer treatment reviews.

Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study.

A. Jimeno, F. Rivera, R. García-Carbonero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.

A. Abad, B. Massuti, F. Rivera, 2013, Clinical colorectal cancer.

Gold Glyconanoparticles Combined with 91–99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors

F. Rivera, M. Marradi, H. Terán-Navarro, 2022, Cancers.

Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer.

A. Carrato, C. Köhne, M. Peeters, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment.

J. Canon, M. Peeters, T. Price, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis

J. Douillard, M. Valladares-Ayerbes, F. Rivera, 2016 .

Molecular Pathology: Poster#249 RAS MUTATIONS DISTRIBUTION IN A 108 PATIENTS SERIES OF COLORECTAL CANCER

F. Rivera, J. Gómez-Román, J. Freire, 2014 .

GNP-GAPDH1-22 nanovaccines prevent neonatal listeriosis by blocking microglial apoptosis and bacterial dissemination

M. Fresno, F. Rivera, I. García, 2017, Oncotarget.

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.

Edward J. Kim, P. Philip, J. Lacy, 2020, The lancet. Gastroenterology & hepatology.

PD-014First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

A randomized phase III study comparing adjuvant 5-ﬂuorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer

C. Bokemeyer, M. Ychou, W. Hohenberger, 2009 .

Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301)

C. Bokemeyer, M. Ychou, P. Gascón, 2008 .

Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat-study.

D. Cunningham, M. Michael, S. Berry, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN)

C. Borel, A. Awada, F. Rivera, 2003 .

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

P. Gibbs, L. Diaz, Ping Yang, 2020, Journal of Clinical Oncology.

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.

J. Mayordomo, L. Paz-Ares, R. Hitt, 1995, Journal of the National Cancer Institute.

Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC).

J. Tabernero, J. Canon, G. Bodoky, 2015 .

Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients.

J. Mayordomo, L. Paz-Ares, M. D. García-Prats, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

F. Rivera, C. Pericay, F. Alvarez-Manceñido, 2017, Gastric Cancer.

NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis.

M. Alsina, F. Rivera, J. Gallego, 2013 .

A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.

J. Tabernero, M. Moore, F. Rivera, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC).

J. Tabernero, F. Ciardiello, M. Valladares-Ayerbes, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of G-CSF and GM-CSF in the treatment of febrile neutropenia induced by chemotherapy ; preliminary results of a randomized trial

J. Mayordomo, L. Paz-Ares, F. Rivera, 1994 .

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.

P. Gibbs, Ping Yang, C. Punt, 2021 .

E. Van Cutsem, M. Amonkar, D. Smith, 2020, Annals of Oncology.

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).

Cristina Santos, R. Goldberg, J. Tabernero, 2022, European journal of cancer.

NEOHX study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—18 m DFS analysis.

M. Alsina, F. Rivera, E. Aranda, 2015 .

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

E. Van Cutsem, A. Benson, J. Tabernero, 2015, European journal of cancer.

Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

A. Carrato, F. Rivera, R. López, 2015, Expert review of pharmacoeconomics & outcomes research.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

F. Rivera, S. López-Tarruella, M. E. Vega-Villegas, 2009, Cancer treatment reviews.

Leiomyosarcoma of the Soft Tissues in a Patient with Nevoid Basal-Cell Carcinoma Syndrome

J. Mayordomo, M. D. García-Prats, C. Ballestín, 1994, Tumori.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

M. Alsina, B. Massuti, M. Valladares-Ayerbes, 2013, Cancer Chemotherapy and Pharmacology.

Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy.

M. Hidalgo, J. Tabernero, L. Paz-Ares, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

SEOM guidelines for cervical cancer

F. Rivera, A. Oaknin, V. Rodríguez-Freixinós, 2012, Clinical and Translational Oncology.

On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.

F. Rivera, M. Garrido, P. Jiménez-Fonseca, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

J. Hecht, R. Salazar, E. Van Cutsem, 2012, The Lancet. Oncology.

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer

L. Paz-Ares, A. Carnero, F. Rivera, 2015, Oncotarget.

Mutations in BRIP1 confer high risk of ovarian cancer

A. Gylfason, D. Gudbjartsson, A. Sigurdsson, 2011, Nature Genetics.

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry

Alberto Carmona-Bayonas, Federico Longo, F. Rivera, 2017, British Journal of Cancer.

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

F. Rivera, M. Valladares, N. López-Martínez, 2017, Journal of medical economics.

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

E. Felip, R. Andrés, F. Rivera, 2016, Clinical and Translational Oncology.

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

C. Bokemeyer, M. Ychou, A. Santoro, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

M. Hidalgo, F. López-Ríos, F. Rojo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.

F. Rivera, A. Cervantes, P. Sánchez‐Rovira, 2006, International journal of radiation oncology, biology, physics.

Current controversies in the management of metastatic colorectal cancer

M. Valladares-Ayerbes, F. Rivera, C. Pericay, 2015, Cancer Chemotherapy and Pharmacology.

Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma

A. Carrato, J. Tabernero, B. Massuti, 2010, Cancer Chemotherapy and Pharmacology.

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

F. J. Ramos, J. Baselga, F. Rojo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

L. Paz-Ares, A. Carnero, F. Rivera, 2014, BMC Cancer.

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility

Kari Stefansson, Brian T Helfand, Torben Hansen, 2011, Nature Genetics.

A genome-wide association study yields five novel thyroid cancer risk loci

Sandya Liyanarachchi, Kari Stefansson, Gudmar Thorleifsson, 2017, Nature Communications.

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

A. Carrato, J. Tabernero, J. García-Foncillas, 2012, PloS one.

SEOM guidelines for gastrointestinal stromal sarcomas (GIST)

F. Rivera, A. Poveda, Javier Martín, 2012, Clinical and Translational Oncology.

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status

J. Douillard, M. Peeters, F. Rivera, 2015, Drugs.

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.

M. Alsina, F. Rivera, E. Aranda, 2021, European journal of cancer.

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

F. Rivera, R. García-Carbonero, E. Díaz-Rubio, 2020, ESMO Open.

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).

J. Bendell, A. Ko, F. Rivera, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.

M. Peeters, T. Price, F. Rivera, 2019, Clinical colorectal cancer.

Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study.

F. Rivera, J. López-Martín, M. Benavides, 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Mutations in BRIP 1 / FANCJ confer high risk of ovarian cancer

Kari, Gisli, A. Gylfason, 2015 .

Discovery of common variants associated with low TSH levels and thyroid cancer risk

Kari Stefansson, Gudmar Thorleifsson, Jon Hrafnkelsson, 2012, Nature Genetics.

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.

F. López-Ríos, F. Lordick, J. Aparicio, 2014, Cancer letters.

E. Van Cutsem, Ping Yang, C. Punt, 2021, The Lancet. Oncology.

Validation of the gene signature predictive of response to chemotherapy in mCRC patients

L. Paz-Ares, A. Carnero, F. Rivera, 2015 .

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).

M. Valladares-Ayerbes, F. Rivera, C. Pericay, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus on the treatment of pancreatic cancer in Spain

M. Hidalgo, J. Tabernero, A. Abad, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.

F. Rivera, E. Martin, M. S. Fernández, 2020 .

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

J. Tabernero, M. Moore, J. Maurel, 2014, The oncologist.

Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

J. Tabernero, L. Paz-Ares, X. G. Del Muro, 2009, Marine drugs.

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

A. Carrato, J. Tabernero, J. García-Foncillas, 2014, Clinical and Translational Oncology.

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.

Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification

F. Rivera, R. García-Carbonero, C. Grávalos, 2007 .

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

R. Salazar, E. Van Cutsem, J. Tabernero, 2013, Clinical Cancer Research.

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

S. Reingold, W. Scheithauer, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

F. Rivera, V. Arrazubi, P. Jiménez-Fonseca, 2019, Cancer Chemotherapy and Pharmacology.

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

A. Jimeno, F. Rivera, R. García-Carbonero, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

C. Tournigand, M. Buyse, I. Chirivella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

P. Gibbs, C. Punt, Tae Won Kim, 2021 .

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

J. Jassem, J. Canon, J. Douillard, 2010 .

A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

F. Rivera, C. Pericay, A. Irigoyen, 2010 .

Colony-stimulating factors for adjunctive therapy of infections in neutropenic cancer patients

J. Mayordomo, F. Rivera, H. Cortés-Funes, 2004, Supportive Care in Cancer.

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

A. Carrato, A. Abad, B. Massuti, 2017, European journal of cancer.

Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

C. Tournigand, M. Buyse, I. Chirivella, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ef ﬁ cacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

J. Jassem, J. Canon, Y. Humblet, 2014 .

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.

A. Carrato, J. Tabernero, A. Abad, 2009, Critical reviews in oncology/hematology.

Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

A. Carrato, A. Abad, M. Guillot, 2000, Revista de Oncología.

Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II–III rectal cancer

R. Salazar, B. Massuti, F. Rivera, 2012, Clinical and Translational Oncology.

SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)

F. Rivera, A. Férnández-Montes, C. Gómez-Martín, 2022, Clinical and Translational Oncology.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

C. Bokemeyer, E. Van Cutsem, J. Tabernero, 2015 .

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

M. Lowery, L. Wyrwicz, F. Rivera, 2023, Annals of Oncology.

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

B. Massuti, D. Castellano, F. Rivera, 2013, BMC Cancer.

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

M. Peeters, M. Valladares-Ayerbes, F. Rivera, 2017, Journal of Cancer Research and Clinical Oncology.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014 .

Guideline for the diagnosis and treatment of esophageal cancer ( 2016 )

M. Alsina, F. Rivera, V. Arrazubi, 2016 .

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

F. Rivera, R. López, C. Grávalos, 2018, European journal of cancer.

Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy

A. Jimeno, F. Rivera, C. Grávalos, 2005 .

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

J. Bourhis, C. Borel, A. Schueler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.

C. Tournigand, M. Buyse, A. Figer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

A. Carrato, J. Ajani, J. Jassem, 2015, Journal of Gastrointestinal Cancer.

SEOM guidelines for endometrial cancer

F. Rivera, A. Oaknin, V. Rodríguez-Freixinós, 2012, Clinical and Translational Oncology.

Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).

Edward J. Kim, P. Philip, J. Lacy, 2017 .

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

M. Hidalgo, F. Rivera, A. M. Muñoz Martín, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia

J. Mayordomo, V. Guillem, L. Paz-Ares, 1999 .

Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer

F. Rivera, M. Ramos, R. Barceló, 2006, Anti-cancer drugs.

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma

F. Rivera, C. Pericay, C. Gómez-Martín, 2016, Cancer medicine.

Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.

A. Carrato, J. Tabernero, B. Massuti, 2009, International journal of radiation oncology, biology, physics.

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

A. Carrato, J. Tabernero, A. Abad, 2008, Acta oncologica.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer

F. Rivera, R. García-Carbonero, R. Vera, 2017, Clinical and Translational Oncology.

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.

R. Salazar, E. Van Cutsem, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC)

J. Mayordomo, F. Rivera, D. Isla, 2008, Cancer Chemotherapy and Pharmacology.

Abstract 2610: TYMS and XRCC1 gene polymorphisms as possible predictors for the addition of oxaliplatin to 5FU in the adjuvant treatment of stage II and III colorectal cancer

R. Salazar, A. Abad, F. Rivera, 2010 .

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

L. Paz-Ares, A. Carnero, F. Rivera, 2014, BMC Cancer.

J. Canon, M. Peeters, G. Pentheroudakis, 2018, British Journal of Cancer.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

PANOVA-2: A phase II study of TTFields (150kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma - Updated efficacy results.

F. Rivera, J. López-Martín, M. Benavides, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma.

D. Betticher, F. Rivera, J. López-Martín, 2016 .

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer

P. Gibbs, C. Punt, Tae Won Kim, 2022, Cancer science.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT

D. Cunningham, M. Michael, S. Berry, 2008 .

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

J. Aparicio, F. Rivera, Montserrat Muñoz, 2016, Clinical and Translational Oncology.

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.

E. Polo, M. Valladares-Ayerbes, F. Rivera, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?

F. Rivera, M. Salgado, C. Pericay, 2020, International Journal of Colorectal Disease.

Seom guidelines for the treatment of gastric cancer 2015

A. Carrato, C. García-Girón, F. Rivera, 2015, Clinical and Translational Oncology.

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer

L. Paz-Ares, A. Carnero, F. Rivera, 2015 .

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

W. Scheithauer, L. Saltz, A. Figer, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group.

F. Rivera, M. Benavides, E. Aranda, 2014 .

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

M. Guillot, M. Valladares-Ayerbes, F. Rivera, 2023, Clinical colorectal cancer.

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

M. Peeters, M. Valladares-Ayerbes, F. Rivera, 2018, Journal of Cancer Research and Clinical Oncology.

PD-031An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials

J. Douillard, M. Valladares-Ayerbes, F. Rivera, 2016 .

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

E. Van Cutsem, A. Benson, J. Tabernero, 2015, European journal of cancer.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, F. Rivera, 2012, The oncologist.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The Oncologist.

Optimal dose of cetuximab administered every 2 weeks (q2w): A phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)

J. Baselga, F. Rojo, J. Tabernero, 2007 .

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

A. Carrato, A. Abad, M. Valladares-Ayerbes, 2017, European journal of cancer.

A. Carrato, J. Tabernero, A. Abad, 2009, Critical reviews in oncology/hematology.

Abstract 27: Chemotherapy-induced Akt survival signaling is regulated by CD44- Ezrin/Radaxin Moesin (ERM) scaffolding, dependent on EGFR activity

Shiladitya Sengupta, A. Goldman, F. Rivera, 2012 .

V. Heinemann, J. Douillard, F. Rivera, 2016, European journal of cancer.

Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer.

J. Ajani, J. Tabernero, M. Alsina, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.

5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer.

I. Chirivella, A. Figer, F. Rivera, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

306 Optimox study: Folfox7 compared to folfox4 in metastatic colorectal cancer (CRC). Results of a randomized study

A. Figer, F. Rivera, A. Gramont, 2003 .

Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC).

J. Douillard, M. Peeters, T. Price, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC).

C. García-Girón, F. Rivera, C. Martín, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.